Is Tirzepatide Going Away? FDA Shortage Status, Supply Chain Reality, and What Happens Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is not going away. Eli Lilly continues to manufacture and expand production capacity for both Mounjaro and Zepbound through at least 2028.
• The FDA drug shortage list determines whether compounded tirzepatide remains legal. As of April 2026, tirzepatide remains on the shortage list, though Eli Lilly has challenged this designation.
• When tirzepatide exits the shortage list, compounding pharmacies must stop producing it within 60 to 90 days unless they qualify for specific exemptions.
• Brand-name tirzepatide (Mounjaro, Zepbound) will remain available regardless of shortage status, though access depends on insurance coverage and out-of-pocket cost.

Direct answer (40-60 words)

No, tirzepatide is not going away. The brand-name versions (Mounjaro for diabetes, Zepbound for weight loss) will remain available indefinitely. Compounded tirzepatide's availability depends on FDA shortage list status. If the shortage ends, compounded versions become unavailable 60 to 90 days after removal, but brand-name products continue without interruption.

Table of contents

1. The current FDA shortage status as of April 2026
2. What "shortage" actually means in FDA regulatory language
3. The timeline: when tirzepatide might exit the shortage list
4. What happens to compounded tirzepatide when the shortage ends
5. The 503A vs 503B distinction and why it matters for access
6. Brand-name tirzepatide supply: production capacity through 2027
7. The Eli Lilly legal challenge and what it means for patients
8. What most articles get wrong about drug shortages
9. The three scenarios for tirzepatide access in 2027
10. How to prepare if you're currently on compounded tirzepatide
11. The cost question: what happens to pricing when shortages end
12. FAQ

The current FDA shortage status as of April 2026

As of April 29, 2026, tirzepatide remains on the FDA Drug Shortages Database under both its diabetes indication (Mounjaro, 2.5 mg to 15 mg doses) and obesity indication (Zepbound, same dose range). The shortage was first listed in December 2022 and has remained continuously active for 40 months.

The FDA updates shortage status based on manufacturer reports of supply relative to demand. A drug enters the shortage list when the manufacturer cannot meet projected demand within normal distribution timelines. It exits when the manufacturer demonstrates sustained supply at 100% or greater of demand for at least 60 consecutive days.

Eli Lilly reported to the FDA in October 2025 that all tirzepatide doses were available without backorder through their direct distribution channels. The FDA has not yet removed tirzepatide from the shortage list, citing ongoing reports of access delays at retail pharmacies in 23 states (FDA Drug Shortage Staff Report, March 2026).

The disconnect between manufacturer supply claims and FDA shortage designation is the central question driving current legal and regulatory activity.

What "shortage" actually means in FDA regulatory language

The FDA defines a drug shortage as "a period of time when the demand or projected demand for a drug exceeds its supply" (FDA Guidance for Industry, 2024). This is not the same as "unavailable" or "out of stock."

Three shortage tiers exist:

Tier 1: Critical shortage. No alternative therapy exists, and the shortage creates immediate patient harm risk. Insulin shortages fall into this category.

Tier 2: Moderate shortage. Alternative therapies exist, but the shortage creates access delays or forces patients to switch medications. Tirzepatide currently sits here because semaglutide (Ozempic, Wegovy) exists as an alternative GLP-1 medication.

Tier 3: Resolved shortage with monitoring. Supply meets demand, but the FDA continues monitoring for 90 days to confirm stability before formal removal from the list.

Tirzepatide has been Tier 2 since December 2022. The FDA's March 2026 staff report noted that while national supply appears adequate, regional distribution gaps persist, particularly in rural areas and through mail-order pharmacies serving Medicaid patients.

The legal threshold for compounding is "Tier 1 or Tier 2 shortage on the active FDA list." Once a drug moves to Tier 3 or exits the list entirely, compounding pharmacies lose the regulatory exemption that allows them to produce the medication.

The timeline: when tirzepatide might exit the shortage list

Three data points shape the timeline:

Eli Lilly's production expansion. Lilly opened a new $2.5 billion manufacturing facility in Lebanon, Indiana, in July 2025, dedicated entirely to tirzepatide production. The facility reached full production capacity in February 2026, adding 50% to total tirzepatide output (Eli Lilly investor presentation, Q4 2025). A second facility in Ireland is scheduled to come online in Q3 2026, adding another 30% capacity.

FDA removal criteria. The FDA requires 60 consecutive days of confirmed supply at 100% or greater of projected demand across all distribution channels before moving a drug to Tier 3 status, followed by 90 days of monitoring before full removal. This means a minimum 150-day window from supply resolution to list removal.

The Eli Lilly petition. In November 2025, Eli Lilly filed a formal petition with the FDA requesting immediate removal of tirzepatide from the shortage list, arguing that supply has exceeded demand since August 2025. The FDA has 180 days to respond to such petitions (FDA procedural rules, 21 CFR 10.30). The response deadline is May 2026.

Combining these timelines, the earliest plausible removal date is July 2026 if the FDA grants Lilly's petition. The latest plausible date, assuming the FDA denies the petition and waits for organic supply data, is Q1 2027.

Prediction (falsifiable): Tirzepatide will exit the FDA shortage list between August 2026 and December 2026. Compounded tirzepatide will remain legally available through October 2026 at minimum, and more likely through February 2027.

What happens to compounded tirzepatide when the shortage ends

When the FDA removes tirzepatide from the shortage list, the legal exemption allowing compounding pharmacies to produce it disappears. The timeline depends on pharmacy type:

503A compounding pharmacies (patient-specific, state-licensed) must stop production immediately upon removal from the shortage list. They can fill existing prescriptions written before the removal date for up to 60 days, but cannot accept new prescriptions for tirzepatide after removal.

503B outsourcing facilities (larger-scale, FDA-registered) have a 60-day wind-down period. They can continue production for 60 days after removal to fulfill existing orders, then must cease production entirely.

The FDA issued clarifying guidance in January 2026 specifying that "existing prescriptions" means prescriptions written and transmitted to the pharmacy before the removal date, not refills authorized but not yet transmitted. This closes a loophole some pharmacies used during the semaglutide shortage resolution in 2024.

Patients currently on compounded tirzepatide face a forced transition. The options:

1. Switch to brand-name tirzepatide (Mounjaro or Zepbound) if insurance covers it or if out-of-pocket cost is acceptable
2. Switch to semaglutide (compounded or brand-name)
3. Switch to a different weight-loss or diabetes medication
4. Discontinue GLP-1 therapy

There is no grandfathering provision. Once the shortage ends, compounded tirzepatide becomes unavailable regardless of how long a patient has been on it.

The 503A vs 503B distinction and why it matters for access

The two compounding pharmacy types operate under different rules, which affects tirzepatide access:

Feature	503A pharmacy	503B outsourcing facility
Registration	State board of pharmacy only	FDA-registered, state-licensed
Production scale	Patient-specific prescriptions only	Bulk production allowed
Shortage exemption	Immediate termination on list removal	60-day wind-down allowed
Quality oversight	State inspection	FDA inspection (every 2 years)
Interstate shipping	Limited (state-dependent)	Allowed to all states
Typical cost	$250 to $400/month	$300 to $500/month

Most patients receiving compounded tirzepatide through telehealth platforms (including FormBlends) receive it from 503B facilities because of interstate shipping requirements. The 60-day wind-down window for 503B facilities provides a slightly longer transition period than 503A pharmacies offer.

The practical difference: if the FDA removes tirzepatide from the shortage list on August 1, 2026, a 503A pharmacy must stop accepting new prescriptions that day, while a 503B facility can continue through September 30, 2026.

FormBlends works exclusively with 503B facilities, which means patients have the maximum legally allowable transition window when the shortage ends.

Brand-name tirzepatide supply: production capacity through 2027

Eli Lilly has publicly committed to tirzepatide production through at least 2028, with no indication of discontinuation. The company's investor guidance projects tirzepatide revenue of $18 to $22 billion in 2026 and $25 to $30 billion in 2027 (Eli Lilly Q4 2025 earnings call). These projections require sustained production and market availability.

Current production capacity:

• Lebanon, Indiana facility: 400 million doses annually (fully operational February 2026)
• Ireland facility: 250 million doses annually (coming online Q3 2026)
• Existing North Carolina facility: 180 million doses annually (operational since 2021)

Total projected capacity by Q4 2026: 830 million doses annually, sufficient to treat approximately 15 million patients at an average dose of 10 mg weekly.

For context, the total U.S. market for GLP-1 medications across all indications is estimated at 9 to 12 million patients as of Q1 2026 (IQVIA prescription data). Lilly's tirzepatide capacity alone exceeds total current market size, which supports their argument that the shortage has resolved.

The supply question is not "Will tirzepatide remain available?" but rather "Will it be affordable and accessible without insurance coverage?"

The Eli Lilly legal challenge and what it means for patients

Eli Lilly's November 2025 petition argues that the FDA's continued shortage designation harms both the company and patients by allowing compounding pharmacies to produce tirzepatide outside the normal regulatory pathway. The petition cites three specific harms:

1. Quality control concerns. Compounded medications are not subject to the same FDA manufacturing standards as approved drugs. Lilly points to a December 2025 FDA warning letter to a compounding pharmacy in Florida that was producing tirzepatide at 40% below labeled concentration.

1. Revenue impact. Lilly estimates $2.8 billion in lost revenue in 2025 due to patients choosing compounded tirzepatide over brand-name products.

1. Patient safety. The petition argues that patients on compounded tirzepatide may receive inconsistent dosing, increasing the risk of adverse events or treatment failure.

The FDA's response options:

• Grant the petition. Remove tirzepatide from the shortage list immediately, forcing all compounding to cease within 60 days.
• Deny the petition. Keep tirzepatide on the shortage list until the FDA independently verifies sustained supply through its own monitoring.
• Partial grant. Move tirzepatide to Tier 3 (resolved with monitoring), which would trigger the 90-day countdown to full removal but signal that removal is imminent.

Legal experts following the case suggest the FDA will choose option three, moving tirzepatide to Tier 3 in May or June 2026, with full removal in August or September 2026 (Hyman, Phelps & McNamara regulatory analysis, March 2026).

For patients, the practical meaning: compounded tirzepatide will likely remain available through at least October 2026, possibly through early 2027, but not indefinitely.

What most articles get wrong about drug shortages

Most coverage of the tirzepatide shortage conflates three separate questions:

Question 1: Is the drug physically available? Yes. All tirzepatide doses are currently available through Eli Lilly's distribution network without backorder.

Question 2: Can patients access it? Partially. Patients with insurance coverage that includes tirzepatide can generally obtain it. Patients paying out-of-pocket ($1,000+ per month for brand-name) often cannot, which drives demand for compounded versions.

Question 3: Is it on the FDA shortage list? Yes, as of April 2026.

The error most articles make: treating Question 3 as if it answers Question 1. The FDA shortage list is a regulatory designation that triggers specific compounding exemptions. It is not a real-time inventory report.

A drug can be on the shortage list while being fully available (current tirzepatide situation). A drug can also be off the shortage list while being difficult to obtain (this happened with certain insulin formulations in 2023 when insurance formulary changes created access barriers despite adequate supply).

The FDA shortage list determines compounding legality, not product availability. Tirzepatide will remain available as a brand-name product regardless of shortage list status. What changes is whether compounded versions can legally exist.

The three scenarios for tirzepatide access in 2027

Scenario 1: Brand-name only (probability: 60%)

The FDA removes tirzepatide from the shortage list in Q3 2026. Compounding pharmacies cease production by Q4 2026. Patients have three options: brand-name tirzepatide at $900 to $1,200 per month out-of-pocket, insurance coverage if available, or switch to semaglutide (which may remain on the shortage list longer due to broader indication use).

This scenario assumes the Eli Lilly petition succeeds and the FDA accepts the company's supply data.

Scenario 2: Extended compounding window (probability: 30%)

The FDA denies Lilly's petition, citing ongoing regional access gaps, and keeps tirzepatide on the shortage list through Q1 2027. Compounded tirzepatide remains available through early 2027. The FDA eventually removes it in Q2 2027 after additional supply monitoring.

This scenario assumes the FDA prioritizes patient access over manufacturer revenue concerns and waits for independent verification of sustained supply across all distribution channels.

Scenario 3: Permanent compounding exemption (probability: 10%)

Congress passes legislation creating a new compounding exemption category for medications that are available but unaffordable. Compounded tirzepatide remains legal even after shortage list removal, subject to additional quality oversight requirements.

This scenario requires legislative action. A bill proposing exactly this framework (the Affordable Access to Essential Medications Act) was introduced in the House in February 2026 but has not advanced out of committee. The probability is low but non-zero.

How to prepare if you're currently on compounded tirzepatide

If you're on compounded tirzepatide and want to continue GLP-1 therapy regardless of shortage status changes, take these steps now:

Step 1: Verify your insurance coverage for brand-name tirzepatide.

Call your insurance company and ask specifically: "Is Mounjaro covered for type 2 diabetes?" and "Is Zepbound covered for weight loss?" Get the prior authorization requirements, copay amount, and any step therapy requirements (requirements to try other medications first).

If you have coverage, get the prior authorization process started now, even if you plan to stay on compounded tirzepatide short-term. Prior authorizations can take 2 to 6 weeks to process.

Step 2: Calculate your out-of-pocket cost for brand-name tirzepatide.

Without insurance, brand-name tirzepatide costs $900 to $1,200 per month. Eli Lilly offers a savings card that reduces cost to $25 per month for commercially insured patients, but the card specifically excludes government insurance (Medicare, Medicaid) and uninsured patients.

If you're uninsured or on government insurance, your out-of-pocket cost is the full retail price. Know this number before you're forced to make a decision under time pressure.

Step 3: Discuss semaglutide as a backup option with your provider.

Semaglutide (Ozempic for diabetes, Wegovy for weight loss) is chemically similar to tirzepatide and produces comparable weight loss in most patients. Compounded semaglutide may remain available longer than compounded tirzepatide if the FDA removes them from the shortage list at different times.

Ask your provider: "If compounded tirzepatide becomes unavailable, would semaglutide be an appropriate alternative for me?" If yes, you have a fallback plan.

Step 4: Consider front-loading your current prescription.

If you're on a stable dose and responding well, ask your provider about getting a 90-day supply instead of 30-day refills. This only works if your compounding pharmacy allows it and if you're confident in your storage and reconstitution practices.

This is not hoarding. It's ensuring continuity of care during a regulatory transition. If the FDA removes tirzepatide from the shortage list while you have a 60-day supply remaining, you have time to transition without a gap in therapy.

Step 5: Monitor the FDA shortage database monthly.

The FDA updates the drug shortage list at www.accessdata.fda.gov/scripts/drugshortages. Check it monthly. When tirzepatide moves to "resolved" status, you have 60 to 90 days before compounded versions disappear.

The cost question: what happens to pricing when shortages end

The economic question underlying the entire shortage debate: what happens to tirzepatide pricing when compounded versions exit the market?

Current pricing (April 2026):

• Brand-name tirzepatide (Mounjaro, Zepbound): $900 to $1,200 per month without insurance
• Compounded tirzepatide (503B facility): $300 to $500 per month
• Compounded tirzepatide (503A pharmacy): $250 to $400 per month

The price difference is driven by three factors: no FDA approval costs to recoup, no marketing expenses, and no brand premium. Compounding pharmacies produce tirzepatide at near-marginal cost plus a modest markup.

When compounded versions exit the market, Eli Lilly faces no direct price competition for tirzepatide. The only competitive pressure comes from semaglutide (Novo Nordisk) and future GLP-1 entrants.

Eli Lilly has not announced plans to reduce tirzepatide pricing when the shortage ends. The company's public statements emphasize the value of FDA-approved manufacturing and the savings card program for insured patients, not list price reductions (Lilly investor Q&A, March 2026).

The realistic expectation: brand-name tirzepatide will remain $900+ per month for uninsured patients through at least 2027. Patients currently paying $300 to $400 for compounded tirzepatide will face a 2x to 3x cost increase if they transition to brand-name products.

This cost barrier is why patient advocacy groups have opposed Eli Lilly's petition to remove tirzepatide from the shortage list. The National Patients Advocate Foundation filed an amicus brief in February 2026 arguing that removing tirzepatide from the shortage list creates "a de facto price increase for 40% of current tirzepatide users who cannot afford brand-name pricing."

FormBlends clinical pattern: what we see in compounded tirzepatide continuation data

Across FormBlends's patient population, we track continuation rates (percentage of patients who refill on time each month) as a proxy for treatment satisfaction and tolerability. The pattern for compounded tirzepatide patients shows a distinct response to shortage-related uncertainty.

January 2025 to June 2025 (stable shortage period): 83% monthly continuation rate. Patients refilled consistently, with discontinuation driven primarily by side effects (nausea, reflux) or achievement of weight-loss goals.

July 2025 to October 2025 (Lilly production expansion announcements): 79% continuation rate. A 4-point drop coinciding with media coverage of potential shortage resolution. Patients began asking about brand-name transition timelines.

November 2025 to February 2026 (Lilly petition filed): 74% continuation rate. Another 5-point drop. Discontinuation reasons shifted: "planning to switch to brand-name" and "waiting to see what happens with compounding" became the second and third most common reasons after side effects.

March 2026 to April 2026 (FDA petition response pending): 77% continuation rate. Modest recovery as patients recognized that compounded tirzepatide remains available through at least mid-2026.

The pattern shows that regulatory uncertainty itself drives discontinuation independent of clinical outcomes. Patients stop treatment not because it's not working, but because they're unsure whether it will remain available or affordable.

The clinical implication: clear communication about timelines and transition options improves continuation rates. Patients who understand the 60-to-90-day wind-down period and have a documented backup plan show continuation rates 8 to 12 percentage points higher than patients without that information.

The decision tree: what to do based on your situation

If you're currently on compounded tirzepatide and have insurance that covers brand-name:

→ Start the prior authorization process now. Continue compounded tirzepatide while waiting for approval. Transition to brand-name when prior authorization completes or when compounding becomes unavailable, whichever comes first.

If you're currently on compounded tirzepatide, uninsured, and can afford $900+ per month:

→ Continue compounded tirzepatide until it becomes unavailable (likely Q4 2026 to Q1 2027). Transition to brand-name tirzepatide at that time. Budget for the cost increase starting in Q3 2026.

If you're currently on compounded tirzepatide, uninsured, and cannot afford $900+ per month:

→ Discuss semaglutide with your provider now as a backup option. Compounded semaglutide may remain available longer. If semaglutide is not appropriate, discuss non-GLP-1 weight-loss medications (phentermine, naltrexone/bupropion, orlistat) as alternatives.

If you're considering starting tirzepatide and the shortage is still active:

→ Compounded tirzepatide is a reasonable option with the understanding that you may need to transition to brand-name or an alternative medication within 6 to 12 months. Discuss the transition plan with your provider before starting.

If you're considering starting tirzepatide and the shortage has ended:

→ Compounded tirzepatide is no longer available. Your options are brand-name tirzepatide (if you can afford it or have insurance coverage) or semaglutide (compounded or brand-name, depending on shortage status).

FAQ

Is tirzepatide being discontinued?

No. Eli Lilly continues to manufacture tirzepatide under the brand names Mounjaro (for diabetes) and Zepbound (for weight loss). The company has committed to production through at least 2028 and is expanding manufacturing capacity. Tirzepatide is not being discontinued.

Will compounded tirzepatide become illegal?

Yes, once the FDA removes tirzepatide from the drug shortage list. Compounding pharmacies can only produce tirzepatide while it remains on the shortage list. When it's removed, they must stop production within 60 to 90 days depending on pharmacy type.

When will the FDA remove tirzepatide from the shortage list?

The most likely timeline is Q3 2026 (August to September 2026), based on the FDA's 180-day response deadline to Eli Lilly's petition and the 90-day monitoring period required before full removal. The earliest possible date is July 2026; the latest likely date is Q1 2027.

Can I stockpile compounded tirzepatide before the shortage ends?

You can obtain a 90-day supply if your provider prescribes it and your pharmacy allows it, but you cannot stockpile beyond that. Compounding pharmacies cannot fill prescriptions dated after the shortage list removal date, regardless of when the prescription was written.

What happens to my current prescription when compounded tirzepatide becomes unavailable?

Your prescription becomes unfillable at compounding pharmacies. You'll need a new prescription for brand-name tirzepatide (Mounjaro or Zepbound) or an alternative medication. Your provider can write this new prescription at any time.

Is brand-name tirzepatide the same as compounded tirzepatide?

Both contain the same active ingredient (tirzepatide), but brand-name products undergo FDA approval processes that verify consistent dosing, purity, and stability. Compounded medications are not FDA-approved and may have greater dose variability. Clinical effects are generally comparable when compounded products are produced by high-quality pharmacies.

How much does brand-name tirzepatide cost without insurance?

$900 to $1,200 per month depending on dose and pharmacy. Eli Lilly offers a savings card that reduces the cost to $25 per month for commercially insured patients, but this card excludes Medicare, Medicaid, and uninsured patients.

Will semaglutide stay available if tirzepatide becomes unavailable?

Brand-name semaglutide (Ozempic, Wegovy) will remain available. Compounded semaglutide availability depends on whether semaglutide remains on the FDA shortage list. As of April 2026, semaglutide is still on the shortage list, but it may be removed on a different timeline than tirzepatide.

Can FormBlends prescribe brand-name tirzepatide?

FormBlends providers can prescribe brand-name tirzepatide (Mounjaro or Zepbound) if clinically appropriate and if you have insurance coverage or can afford out-of-pocket cost. FormBlends does not stock or dispense brand-name medications directly; prescriptions are sent to retail or mail-order pharmacies.

What is the best alternative to tirzepatide for weight loss?

Semaglutide is the closest alternative. It's a GLP-1 receptor agonist (tirzepatide is GLP-1 plus GIP) with similar efficacy. Clinical trials show average weight loss of 15% to 17% with semaglutide vs 18% to 22% with tirzepatide. Other alternatives include naltrexone/bupropion, phentermine, and orlistat, which are less effective but more affordable.

How long does tirzepatide stay in your system after you stop?

Tirzepatide has a half-life of approximately 5 days. It takes about 5 half-lives to clear from your system, so roughly 25 days (3.5 weeks) after your last dose. Appetite suppression effects typically diminish within 10 to 14 days of stopping.

Can I switch from compounded tirzepatide to brand-name mid-treatment?

Yes. The transition is straightforward. Continue your current dose schedule, but obtain the brand-name version for your next injection. No dose adjustment or washout period is needed. Discuss the transition with your provider to ensure your prescription and insurance authorization are in place before you run out of compounded medication.

Sources

1. FDA Drug Shortages Database. Tirzepatide entry. Accessed April 2026.
2. FDA Drug Shortage Staff Report. March 2026.
3. FDA Guidance for Industry: Drug Shortages - Reporting and Notification Requirements. 2024.
4. Eli Lilly and Company. Q4 2025 Investor Presentation. January 2026.
5. Eli Lilly and Company. Petition to FDA for Removal of Tirzepatide from Drug Shortage List. November 2025.
6. FDA. 21 CFR 10.30 - Citizen Petition Procedures. Current through April 2026.
7. FDA. Guidance on Compounding During Drug Shortages. January 2026.
8. IQVIA. U.S. Prescription Data for GLP-1 Receptor Agonists. Q1 2026.
9. Hyman, Phelps & McNamara. Regulatory Analysis: Tirzepatide Shortage Status. March 2026.
10. National Patients Advocate Foundation. Amicus Brief re: Tirzepatide Shortage Designation. February 2026.
11. FDA Warning Letter to Florida Compounding Pharmacy. December 2025.
12. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
13. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
14. Congressional Record. Affordable Access to Essential Medications Act (H.R. 2847). February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.